medcelerator · clinician one-pager

Infusion to Reduce Relapses in Childhood Nephrotic Syndrome

Gazyva (obinutuzumab) — infusion to reduce relapse risk in childhood-onset idiopathic nephrotic syndrome

FDA Approved · United States · October 10, 2026

Condition: Idiopathic Nephrotic Syndrome

Who this is for

This is for families and adults living with frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome who are in complete remission and are 2 years or older. It explains the 25 September 2026 FDA approval of intravenous Gazyva (obinutuzumab) to reduce relapse risk, the four-infusion schedule, and what INShore (NCT05627557) showed against mycophenolate mofetil. It is not a home injection, not a lupus, leukemia, or lymphoma use of the same brand, and not an approval outside the United States on sources checked here. Authorized is not funded.

Next clinical step

The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.

General resources for further research

ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/

AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/gazyva-obinutuzumab-ins